- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
Eli Lilly and Novo Nordisk are leading the weight management market, with plans to seek label expansion applications in Europe.
1 report, 1 independent
Updated Jul 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Novo Nordisk are leading the weight management market, with plans to seek label expansion applications in Europe.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Eli Lilly and Novo Nordisk are facing scrutiny regarding their weight loss advertising claims and compliance with bloc safety standards while seeking label expansion in Europe.Sub-event
The two companies plan to submit label expansion applications for their weight loss drugs in Europe.1 source
Keep exploring
Part of
Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.Also in this story
- Novo Nordisk and Eli Lilly are utilizing physician networks in Texas, including Carlos Campos, to promote their weight-loss drugs.
- UK MHRA approved Foundayo for commercialization, marking a significant market entry point in the global obesity drug competition.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Teva obtained FDA approval for a generic drug, challenging Novo Nordisk's market share in the GLP-1RA space.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Eli Lilly and Novo Nordisk are now competing in the basal insulin market segment.
- Eli Lilly and Novo Nordisk are facing scrutiny regarding their name-brand weight loss drugs due to findings during an FDA data review.
Coverage
Newest first; wire copies grouped- Motley FoolShould You Invest in This Under-the-Radar Weight Loss Stock? Rhythm Pharmaceuticals' lone approved product currently generates minimal sales. However, recent clinical progress could help change that